Wexford Capital’s Dianthus Therapeutics DNTH Stock Holding History

Wexford Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-352	Closed	-$44K	–	244
2020 Q4	$44K	Buy	+352	New	+$39.9K	0.01%	193

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wexford Capital's DNTH Position: Q1 2021 in Review

Wexford Capital sold out of Dianthus Therapeutics (DNTH) in Q1 2021, closing a stake of 352 shares — an estimated $44K sold.

Wexford Capital first reported a position in DNTH in Q4 2020 and held it in 1 quarter. The position peaked at $44K in Q4 2020. 90 funds tracked by Wall St. Rank hold DNTH as of Q1 2021.

Wexford Capital reported no remaining Dianthus Therapeutics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 352 Dianthus Therapeutics shares in Q1 2021, an estimated $44K.
Wexford Capital first reported a position in Dianthus Therapeutics in Q4 2020 and held it in 1 quarter.
Wexford Capital's Dianthus Therapeutics position peaked at $44K in Q4 2020.
90 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.